Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Helsinn ANAM-17-21:Non-Small Cell Lung Cancer and weight loss - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how Anamorelin HCl works to prevent weight loss and anorexia in patients with advanced NSCLC.
What is the Condition Being Studied?
Non-Small Cell Lung Cancer

Who Can Participate in the Study?

Adults who:
-Have advanced NSCLC
-Are experiencing weight loss and/or appetite problems

Age Group

What is Involved?

If you choose to join this study, you will:
-Be in this study for up to 27 weeks
-Be randomized (like the flip of a coin) to get the study drug (Anamorelin HC1) or a placebo (harmless medicine)
-Give blood samples
-Complete regular care and visits

Study Details

Full Title
ANAM-17-21 A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101263
NCT: NCT03743064
Phase III
Contact the Duke Recruitment Innovation Center